- Phase 2a Study Showed Statistically Significant Decreases (p

AUSTIN, Texas , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that clinical results of its Phase 2a study of PTI-125 have been selected as a late-breaking oral presentation by the

First two patients dosed with lead drug candidate, PTI-125 Study initiation follows positive Phase 2a results demonstrating 100% response rate AUSTIN, Texas , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biopharmaceutical company focused on

Lead drug candidate, PTI-125, significantly decreased key biomarkers of neuroinflammation and neurodegeneration in all study patients (p<.001 clinical="" data="" support="" initiation="" of="" a="" phase="" study="" in="" alzheimer="" q3="" austin="" texas="" sept.="" newswire="" cassava="" sciences="" inc.="">

AUSTIN, Texas , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biotechnology company, announced today that Remi Barbier , President & CEO, will present a corporate and clinical overview at H.C. Wainwright’s 21 st Annual Global Investment Conference . 

AUSTIN, Texas , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biopharmaceutical company developing PTI-125 for Alzheimer’s disease, today reported financial results for the second quarter ended June 30, 2019 .

AUSTIN, Texas , June 18, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biotechnology company, announced today that Remi Barbier , its President and CEO, will present at Maxim Group’s conference on Alzheimer’s disease on Wednesday, June 26 th , in New York. 

AUSTIN, Texas , May 28, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biotechnology company, announced today the launch of its newly designed website, www.CassavaSciences.com .  Cassava Sciences’ new website has extensive information on Alzheimer’s disease, a key

2019 Focus is on Fiscal Discipline and Advancing Development Pipeline AUSTIN, Texas , April 29, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a biopharmaceutical company, today reported financial results for the first quarter ended March 31 , 2019.  Net loss was $1.4 million , or

AUSTIN, Texas , April 15, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA ), a clinical-stage biotechnology company, announced the completion of patient enrollment in a clinical study evaluating the safety of its investigational drug, PTI-125, in patients with Alzheimer’s disease.